GFM
AVBP icon

GF Fund Management’s ArriVent BioPharma AVBP Stock Holding History

GF Fund Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.5K Sell
877
-42
-5% -$1.24K ﹤0.01% 444
2026
Q1 		$21.2K Buy
919
+108
+13% +$2.44K ﹤0.01% 497
2025
Q4 		$16.3K Sell
811
-62
-7% -$1.29K ﹤0.01% 528
2025
Q3 		$16.1K Buy
873
+10
+1% +$196 ﹤0.01% 516
2025
Q2 		$18.8K Hold
863
– – ﹤0.01% 508
2025
Q1 		$16K Buy
863
+155
+22% +$3.79K ﹤0.01% 522
2024
Q4 		$18.9K Buy
+708
New +$20.3K ﹤0.01% 477

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GF Fund Management's AVBP Position: Q2 2026 in Review

GF Fund Management reduced its ArriVent BioPharma (AVBP) stake by 4.6% in Q2 2026, selling an estimated $1.24K and leaving 877 shares worth $30.5K. The position accounts for ﹤0.01% of the portfolio, ranked #444.

GF Fund Management first reported a position in AVBP in Q4 2024 and has held it in 7 quarters since. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • GF Fund Management held 877 shares of ArriVent BioPharma worth $30.5K as of Q2 2026.
  • GF Fund Management sold 42 ArriVent BioPharma shares in Q2 2026, an estimated $1.24K.
  • ArriVent BioPharma made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #444 holding.
  • GF Fund Management first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 7 quarters since.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.